Truist Financial Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $796.00

Truist Financial Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $796.00

Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating for the company in a research report on Thursday.

Regeneron Pharmaceuticals Non-GAAP EPS of $9.47 beats by $0.57, revenue of $3.61B beats by $130M (REGN:NASDAQ)

Regeneron (REGN) Q1 earnings: EPS and revenue beat, Dupixent and EYLEA sales trends, new $3B buyback, and updated 2026 guidance—read more now.

Regeneron Q1 2026 net income falls 10% to $727m

Regeneron Pharmaceuticals has reported GAAP net income of $727m for Q1 2026, down 10% from $809m in Q1 2025.